Nobiletin, a Citrus Flavonoid, Improves Memory Impairment and Aβ Pathology in a Transgenic Mouse Model of Alzheimer’s Disease
Authors:
- Akira NakajimaANAkira Nakajima
- Kentaro MatsuzakiKentaro Matsuzaki
- Ryong-Woon ShinRSRyong-Woon Shin
- Koichi OginoKOKoichi Ogino
- Daisuke SaigusaDSDaisuke Saigusa
- Naomi TetsuNTNaomi Tetsu
- Akihito YokosukaAkihito Yokosuka
- Yutaka SashidaYSYutaka Sashida
- Yoshihiro MimakiYMYoshihiro Mimaki
- Tohru YamakuniTYTohru Yamakuni
- Yasushi OhizumiYOYasushi Ohizumi
- 1 September 2008
- journal article
- research article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 326 (3) , 739-744
Abstract
Increasing evidence suggests that the elevation of β-amyloid (Aβ) peptides in the brain is central to the pathogenesis of Alzheimer9s disease (AD). Our recent studies have demonstrated that nobiletin, a polymethoxylated flavone from citrus peels, enhances cAMP/protein kinase A/extracellular signal-regulated kinase/cAMP response element-binding protein signaling in cultured hippocampal neurons and ameliorates Aβ-induced memory impairment in AD model rats. For the first time, we report that this natural compound improves memory deficits in amyloid precursor protein (APP) transgenic mice that overexpress human APP695 harboring the double Swedish and London mutations [APP-SL 7-5 transgenic (Tg) mice]. Our enzyme-linked immunosorbent assay (ELISA) also showed that administration of nobiletin to the transgenic mice for 4 months markedly reduced quantity of guanidine-soluble Aβ1–40 and Aβ1–42 in the brain. Furthermore, consistent with the results of ELISA, by immunohistochemistry with anti-Aβ antibody, it was evidently shown that the administration of nobiletin decreased the Aβ burden and plaques in the hippocampus of APP-SL 7-5 Tg mice. These findings suggest that this natural compound has potential to become a novel drug for fundamental treatment of AD.Keywords
This publication has 41 references indexed in Scilit:
- Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's diseaseProceedings of the National Academy of Sciences, 2006
- The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to TherapeuticsScience, 2002
- Learning and Memory in Transgenic Mice Modeling Alzheimer's DiseaseLearning & Memory, 2001
- β-Amyloid Activates the Mitogen-Activated Protein Kinase Cascade via Hippocampal α7 Nicotinic Acetylcholine Receptors:In VitroandIn VivoMechanisms Related to Alzheimer's DiseaseJournal of Neuroscience, 2001
- The MAPK cascade is required for mammalian associative learningNature Neuroscience, 1998
- A Requirement for the Mitogen-activated Protein Kinase Cascade in Hippocampal Long Term PotentiationJournal of Biological Chemistry, 1997
- AßT Amyloidogenesis: Unique, or Variation on a Systemic ThemeCritical Reviews in Biochemistry and Molecular Biology, 1997
- Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic MiceScience, 1996
- Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's diseaseNeurology, 1992
- N-methyl-D-aspartate receptor antagonist APV blocks acquisition but not expression of fear conditioning.Behavioral Neuroscience, 1991